Literature DB >> 21921738

Increased endothelial progenitor cells and vasculogenic factors in higher-staged arteriovenous malformations.

Lingge Lu1, Joyce Bischoff, John B Mulliken, Diane R Bielenberg, Steven J Fishman, Arin K Greene.   

Abstract

UNLABELLED: ACKGROUND:: Arteriovenous malformations cause significant morbidity, primarily because they expand over time and recur after treatment. The authors hypothesized that neovascularization might contribute to arteriovenous malformation progression.
METHODS: Arteriovenous malformation tissue was collected prospectively from 12 patients after resection. Schobinger stage was determined by clinical history. Neovascularization in stage II lesions (n=7) was compared with stage III arteriovenous malformations (n=5) that had progressed. Specimens were analyzed using immunohistochemistry for CD31, Ki67, and CD34/CD133. Quantitative real-time reverse-transcriptase polymerase chain reaction was used to determine mRNA expression of factors that recruit endothelial progenitor cells: vascular endothelial growth factor (VEGF), stromal cell-derived factor-1α (SDF-1α), and hypoxia-inducible factor-1α (HIF-1α). VEGF receptors (VEGFR1, VEGFR2, neuropilin 1, and neuropilin 2) also were quantified using quantitative real-time reverse-transcriptase polymerase chain reaction.
RESULTS: Stage III arteriovenous malformations showed greater microvessel density (5.8 percent) than stage II lesions (1.3 percent) (p=0.004); no difference in proliferating endothelial cells was noted (p=0.67). CD133CD34 endothelial progenitor cells were elevated in stage III (0.53 percent) compared with stage II arteriovenous malformations (0.25 percent) (p=0.03). HIF-1α and SDF-1α were increased 7.6- and 7.9-fold in stage III compared with stage II lesions (1.7-fold and 3.3-fold), respectively (p=0.02). Neuropilin 1 and neuropilin 2 expression was greater in stage III (5.8-fold and 4.6-fold) than stage II arteriovenous malformations (3.0-fold and 2.4-fold) (p=0.03).
CONCLUSIONS: Higher-staged arteriovenous malformations exhibit increased expression of endothelial progenitor cells and factors that stimulate their recruitment. Neovascularization by vasculogenesis may be involved in progression of arteriovenous malformation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21921738      PMCID: PMC4066897          DOI: 10.1097/PRS.0b013e3182268afd

Source DB:  PubMed          Journal:  Plast Reconstr Surg        ISSN: 0032-1052            Impact factor:   4.730


  59 in total

1.  Contribution of bone marrow-derived endothelial cells to human tumor vasculature.

Authors:  Brock A Peters; Luis A Diaz; Kornelia Polyak; Leslie Meszler; Kathy Romans; Eva C Guinan; Joseph H Antin; David Myerson; Stanley R Hamilton; Bert Vogelstein; Kenneth W Kinzler; Christoph Lengauer
Journal:  Nat Med       Date:  2005-02-20       Impact factor: 53.440

2.  Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis.

Authors:  Yuval Shaked; Francesco Bertolini; Shan Man; Michael S Rogers; Dave Cervi; Thomas Foutz; Kimberley Rawn; Daniel Voskas; Daniel J Dumont; Yaacov Ben-David; Jack Lawler; Jack Henkin; Jim Huber; Daniel J Hicklin; Robert J D'Amato; Robert S Kerbel
Journal:  Cancer Cell       Date:  2005-01       Impact factor: 31.743

3.  Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion.

Authors:  Akira Orimo; Piyush B Gupta; Dennis C Sgroi; Fernando Arenzana-Seisdedos; Thierry Delaunay; Rizwan Naeem; Vincent J Carey; Andrea L Richardson; Robert A Weinberg
Journal:  Cell       Date:  2005-05-06       Impact factor: 41.582

4.  Bone marrow origin of endothelial progenitor cells responsible for postnatal vasculogenesis in physiological and pathological neovascularization.

Authors:  T Asahara; H Masuda; T Takahashi; C Kalka; C Pastore; M Silver; M Kearne; M Magner; J M Isner
Journal:  Circ Res       Date:  1999-08-06       Impact factor: 17.367

5.  Arteriovenous malformations in mice lacking activin receptor-like kinase-1.

Authors:  L D Urness; L K Sorensen; D Y Li
Journal:  Nat Genet       Date:  2000-11       Impact factor: 38.330

6.  Vascular endothelial growth factor expression and tumor angiogenesis are regulated by androgens in hormone responsive human prostate carcinoma: evidence for androgen dependent destabilization of vascular endothelial growth factor transcripts.

Authors:  R J Stewart; D Panigrahy; E Flynn; J Folkman
Journal:  J Urol       Date:  2001-02       Impact factor: 7.450

Review 7.  Regulation of vascular endothelial growth factor expression by estrogens and progestins.

Authors:  S M Hyder; J C Huang; Z Nawaz; H Boettger-Tong; S Mäkelä; C Chiappetta; G M Stancel
Journal:  Environ Health Perspect       Date:  2000-10       Impact factor: 9.031

8.  Increased circulating AC133+ CD34+ endothelial progenitor cells in children with hemangioma.

Authors:  Mark E Kleinman; Oren M Tepper; Jennifer M Capla; Kirit A Bhatt; Daniel J Ceradini; Robert D Galiano; Francine Blei; Jamie P Levine; Geoffrey C Gurtner
Journal:  Lymphat Res Biol       Date:  2003       Impact factor: 2.589

9.  Neovascularization of ischemic myocardium by human bone-marrow-derived angioblasts prevents cardiomyocyte apoptosis, reduces remodeling and improves cardiac function.

Authors:  A A Kocher; M D Schuster; M J Szabolcs; S Takuma; D Burkhoff; J Wang; S Homma; N M Edwards; S Itescu
Journal:  Nat Med       Date:  2001-04       Impact factor: 53.440

10.  Adult vasculogenesis occurs through in situ recruitment, proliferation, and tubulization of circulating bone marrow-derived cells.

Authors:  Oren M Tepper; Jennifer M Capla; Robert D Galiano; Daniel J Ceradini; Matthew J Callaghan; Mark E Kleinman; Geoffrey C Gurtner
Journal:  Blood       Date:  2004-09-23       Impact factor: 22.113

View more
  8 in total

1.  Development of MicroRNA-Based Therapeutics for Vascular Disease.

Authors:  Kia J Jones; Charles D Searles
Journal:  Circ Res       Date:  2020-10-08       Impact factor: 17.367

2.  Expansion of pulmonary arteriovenous malformations after grand mal seizures and other circumstances of PAVM growth.

Authors:  Ami Schattner; Ina Dubin
Journal:  BMJ Case Rep       Date:  2019-08-10

3.  Vertebral Intraosseous Vascular Malformations in a Familial Cerebral Cavernous Malformation Population: Prevalence, Histologic Features, and Associations With CNS Disease.

Authors:  Steven R Tandberg; Thèrése Bocklage; Mary R Bartlett; Leslie A Morrison; Jeffrey Nelson; Blaine L Hart
Journal:  AJR Am J Roentgenol       Date:  2019-12-11       Impact factor: 3.959

4.  A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using 68Ga-RGD PET/CT.

Authors:  Daphne Lobeek; Frédérique C M Bouwman; Erik H J G Aarntzen; Janneke D M Molkenboer-Kuenen; Uta E Flucke; Ha-Long Nguyen; Miikka Vikkula; Laurence M Boon; Willemijn Klein; Peter Laverman; Wim J G Oyen; Otto C Boerman; Samantha Y A Terry; Leo J Schultze Kool; Mark Rijpkema
Journal:  J Nucl Med       Date:  2019-09-13       Impact factor: 10.057

Review 5.  Hypoxia-inducible factor as an angiogenic master switch.

Authors:  Takuya Hashimoto; Futoshi Shibasaki
Journal:  Front Pediatr       Date:  2015-04-24       Impact factor: 3.418

6.  Stemness-Associated Markers Are Expressed in Extracranial Arteriovenous Malformation.

Authors:  Claire S Luke Krishnan; Helen D Brasch; Josie Patel; Nicholas Bockett; Erin Paterson; Paul F Davis; Swee T Tan
Journal:  Front Surg       Date:  2021-03-19

Review 7.  A literature review of microvascular proliferation in arteriovenous malformations of skin and soft tissue.

Authors:  Amalia Mulia Utami; Siham Azahaf; Onno J de Boer; Chantal M A M van der Horst; Lorine B Meijer-Jorna; Allard C van der Wal
Journal:  J Clin Transl Res       Date:  2021-07-30

8.  Hypoxia Promotes Angiogenic Effect in Extracranial Arteriovenous Malformation Endothelial Cells.

Authors:  Joon Seok Lee; Hyun Geun Cho; Jeong Yeop Ryu; Eun Jung Oh; Hyun Mi Kim; Suin Kwak; Seok-Jong Lee; Jongmin Lee; Sang Yub Lee; Seung Huh; Ji Yoon Kim; Ho Yun Chung
Journal:  Int J Mol Sci       Date:  2022-08-14       Impact factor: 6.208

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.